Breeman WA - Search Results

1

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.

de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Béhé M, Powell P, Mäcke HR. de Jong M, et al. Among authors: breeman wa. Eur J Nucl Med. 1997 Apr;24(4):368-71. doi: 10.1007/BF00881807. Eur J Nucl Med. 1997. PMID: 9096086

2

Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.

Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kwekkeboom DJ, Visser TJ, Krenning EP. Breeman WA, et al. J Nucl Med. 2002 Dec;43(12):1650-6. J Nucl Med. 2002. PMID: 12468515 Free article.

3

The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.

Slooter GD, Aalbers AG, Breeman WA, Hiemstra CA, Marquet RL, Krenning EP, van Eijck CH. Slooter GD, et al. Among authors: breeman wa. J Nucl Med. 2002 Dec;43(12):1681-7. J Nucl Med. 2002. PMID: 12468520 Free article.

4

The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.

Breeman WA, van der Wansem K, Bernard BF, van Gameren A, Erion JL, Visser TJ, Krenning EP, de Jong M. Breeman WA, et al. Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):312-5. doi: 10.1007/s00259-002-1054-4. Epub 2002 Nov 29. Eur J Nucl Med Mol Imaging. 2003. PMID: 12552352

5

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.

Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Breeman WA, et al. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20. doi: 10.1007/s00259-003-1142-0. Epub 2003 Apr 4. Eur J Nucl Med Mol Imaging. 2003. PMID: 12677301

6

Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.

Breeman WA, De Jong MT, De Blois E, Bernard BF, De Jong M, Krenning EP. Breeman WA, et al. Nucl Med Biol. 2004 Aug;31(6):821-4. doi: 10.1016/j.nucmedbio.2004.03.008. Nucl Med Biol. 2004. PMID: 15246375

7

Radiolabelling DOTA-peptides with 68Ga.

Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Breeman WA, et al. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):478-85. doi: 10.1007/s00259-004-1702-y. Epub 2005 Jan 18. Eur J Nucl Med Mol Imaging. 2005. PMID: 15655678

8

Tissue distribution of octreotide binding receptors in normal mice and strains prone to autoimmunity.

Ten Bokum AM, Rosmalen JG, Hofland LJ, Krenning EP, Van Hagen PM, Breeman WA. Ten Bokum AM, et al. Among authors: breeman wa. Nucl Med Commun. 2002 Oct;23(10):1009-17. doi: 10.1097/00006231-200210000-00012. Nucl Med Commun. 2002. PMID: 12352601

9

Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.

Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP. Bakker WH, et al. Among authors: breeman wa. Q J Nucl Med Mol Imaging. 2006 Dec;50(4):265-71. Q J Nucl Med Mol Imaging. 2006. PMID: 17043624 Free article. Review.

10

Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.

Rolleman EJ, Bernard BF, Breeman WA, Forrer F, de Blois E, Hoppin J, Gotthardt M, Boerman OC, Krenning EP, de Jong M. Rolleman EJ, et al. Among authors: breeman wa. Nuklearmedizin. 2008;47(3):110-5. doi: 10.3413/nukmed-0069. Nuklearmedizin. 2008. PMID: 18493690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters